169 related articles for article (PubMed ID: 34563497)
1. Bromodomains: A novel target for the anticancer therapy.
Gokani S; Bhatt LK
Eur J Pharmacol; 2021 Nov; 911():174523. PubMed ID: 34563497
[TBL] [Abstract][Full Text] [Related]
2. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
[TBL] [Abstract][Full Text] [Related]
3. Bromodomain Histone Readers and Cancer.
Jain AK; Barton MC
J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
[TBL] [Abstract][Full Text] [Related]
4. Functional Roles of Bromodomain Proteins in Cancer.
Boyson SP; Gao C; Quinn K; Boyd J; Paculova H; Frietze S; Glass KC
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298819
[TBL] [Abstract][Full Text] [Related]
5. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
6. Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.
Li X; Wu Y; Tian G; Jiang Y; Liu Z; Meng X; Bao X; Feng L; Sun H; Deng H; Li XD
J Am Chem Soc; 2019 Jul; 141(29):11497-11505. PubMed ID: 31246451
[TBL] [Abstract][Full Text] [Related]
7. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
To KKW; Xing E; Larue RC; Li PK
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
[TBL] [Abstract][Full Text] [Related]
9. Biological function and histone recognition of family IV bromodomain-containing proteins.
Lloyd JT; Glass KC
J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
[TBL] [Abstract][Full Text] [Related]
10. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
Olp MD; Zhu N; Smith BC
Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain inhibitors and cancer therapy: From structures to applications.
Pérez-Salvia M; Esteller M
Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
[TBL] [Abstract][Full Text] [Related]
12. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
[TBL] [Abstract][Full Text] [Related]
13. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.
Morgado-Pascual JL; Rayego-Mateos S; Tejedor L; Suarez-Alvarez B; Ruiz-Ortega M
Front Pharmacol; 2019; 10():1315. PubMed ID: 31780938
[TBL] [Abstract][Full Text] [Related]
15. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.
Werner MT; Wang H; Hamagami N; Hsu SC; Yano JA; Stonestrom AJ; Behera V; Zong Y; Mackay JP; Blobel GA
J Biol Chem; 2020 Feb; 295(7):1898-1914. PubMed ID: 31792058
[TBL] [Abstract][Full Text] [Related]
16. Aim for the Readers! Bromodomains As New Targets Against Chagas' Disease.
Alonso VL; Tavernelli LE; Pezza A; Cribb P; Ritagliati C; Serra E
Curr Med Chem; 2019; 26(36):6544-6563. PubMed ID: 30378479
[TBL] [Abstract][Full Text] [Related]
17. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching.
Philpott M; Rogers CM; Yapp C; Wells C; Lambert JP; Strain-Damerell C; Burgess-Brown NA; Gingras AC; Knapp S; Müller S
Epigenetics Chromatin; 2014; 7():14. PubMed ID: 25097667
[TBL] [Abstract][Full Text] [Related]
18. Targeting bromodomains: epigenetic readers of lysine acetylation.
Filippakopoulos P; Knapp S
Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
[TBL] [Abstract][Full Text] [Related]
19. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
[TBL] [Abstract][Full Text] [Related]
20. A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.
Flynn EM; Huang OW; Poy F; Oppikofer M; Bellon SF; Tang Y; Cochran AG
Structure; 2015 Oct; 23(10):1801-1814. PubMed ID: 26365797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
